Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyUrologic OncologyDiseaseNeuroendocrine CarcinomaPancreatic CancerProstate CancerSubgroupICD10C25.-C61C80.9MeSHCarcinoma, NeuroendocrinePancreatic NeoplasmsProstatic NeoplasmsSequenceChemotherapyChemo-substanceCapecitabineCisplatinEtoposideIrinotecanTemozolomideChemo-substanceCapecitabineCisplatinEtoposideIrinotecanTemozolomideChemo-substanceCapecitabineCisplatinEtoposideIrinotecanTemozolomideChemo-substanceCapecitabineCisplatinEtoposideIrinotecanTemozolomideNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances37Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaCholangitisDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHypokalemiaHyponatremiaIncrease AminotransferasesNauseaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorApostolidis LMorizane CStrosberg JRDiseaseNeuroendokrines Karzinom des Verdauungstraktes, nicht resezierbar, Erstlinie, ECOG 0-1Neuroendokrines Prostatakarzinom, Erst- und Zweitliniepankreatisches neuroendokrines Karzinom, ErstlinieOriginDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, FloridaDepartment of Medical Oncology, University Hospital HeidelbergJapan Clinical Oncology Group (JCOG), TOPIC-NETProtocols in Revision 4 protocols foundProtocols under revision.Capecitabine 750 / Temozolomide 200, pancreatic neuroendocrine carcinoma (PID1313 V1.1)Cisplatin 25 / Etoposide 100, Neuroendocrine Prostate Cancer (PID1283 V1.1)Cisplatin 60 / Irinotecan 60, gastroenteral and pancreatic neuroendocrine carcinoma (PID2180 V1.0)Cisplatin 80 / Etoposide 100, gastroenteral and pancreatic neuroendocrine carcinoma (PID2174 V1.0)
